MINNEAPOLIS--(BUSINESS WIRE)--Financial advisors Mila Kisz, MBA, and Roman Kisz, AAMS®, CRPS®, recently joined the independent channel of Ameriprise Financial, Inc. (NYSE:AMP) from Edward Jones where they managed $100 million in client assets. The married duo joined an established Ameriprise practice, LegacyOak Advisors, in Simi Valley, Calif., led by financial advisor Greg Lewandowski. The Kisz's and Lewandowski originally met at Edward Jones before Lewandowski moved his practice to Ameriprise.

Cloudflare (NET) shares jumped Tuesday after Bank of America analysts gave the stock a double upgrade, citing strong growth potential in artificial intelligence and security.

Cheesecake Factory revamps its menu with new offerings while discontinuing select items.

NEW YORK CITY, NY / ACCESS Newswire / March 25, 2025 / WHY: New York, N.Y., March 25, 2025.

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=138573&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138572&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Skyworks Solutions, Inc. (NASDAQ:SWKS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/skyworks-solutions-inc-lawsuit-submission-form?prid=138575&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Fluence Energy, Inc. (NASDAQ:FLNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fluence-energy-lawsuit-submission-form?prid=138574&wire=1 or contact Joseph E. Levi, Esq.

Fully managed private AI solution combines cutting-edge AI capabilities with enterprise-grade security and privacy protections Fully managed private AI solution combines cutting-edge AI capabilities with enterprise-grade security and privacy protections

The JPMorgan Equity Premium Income ETF is a popular fund offering eye-opening dividend yields.

The 11th annual secret offering from Lux Row Distillers is finished in Añejo tequila barrels ST. LOUIS , March 25, 2025 /PRNewswire/ -- Lux Row Distillers Master Distiller and Master Blender John Rempe renews his annual pact with bourbon drinkers by releasing Blood Oath Pact 11 Kentucky Straight Bourbon Whiskey Finished in Añejo Tequila Barrels.

YieldMax COIN Option Income Strategy ETF offers high dividends but is risky with an annual expected return of -16% and a potential 70% YoY value loss. CONY uses a synthetic covered call strategy, generating income through call options on COIN, but doesn't directly invest in Coinbase shares. CONY's performance is significantly lower than COIN's, with a 0.39 correlation during bull runs, making it less suitable for capital protection.

Vancouver, British Columbia and West Palm Beach, Florida, March 25, 2025 (GLOBE NEWSWIRE) -- AgriForce Growing Systems Ltd. is proud to announce its participation as keynote speaker at Mining Disrupt 2025, described as the world's premier Bitcoin mining conference, taking place March 25–27 at the Broward Convention Center in Fort Lauderdale, Florida.

PAVmed Inc. (NASDAQ:PAVM ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Jeremy Pearlman - Maxim Group Matthew Park - Cantor Fitzgerald Ed Woo - Ascendiant Capital Operator Good morning, and welcome to PAVmed's Fourth Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.

Like many technology firms, China's Alibaba has been investing in artificial intelligence. However, Alibaba Chairman Joe Tsai said he was “astounded” by the level of AI being planned by the technology sector in the United States, Reuters reported Tuesday (March 25).

Fund managers aim for approximately 80% price upside, maintaining a net short position of around 20% at any time. This strategy balances potential gains with risk management, providing a hedge against market downturns. The approach is designed to optimize returns while minimizing exposure to adverse market conditions.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Geron To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Newswire / March 25, 2025 / If you purchased or acquired securities in Geron between June 7, 2024 to February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Geron Corporation …

Genius Sports Limited (GENI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

NEWARK, Calif.--(BUSINESS WIRE)---- $PENG #AI--SMART Modular announced that it is now sampling its redefined Non-Volatile CXL Memory Module (NV-CMM) to Tier 1 OEMs based on the CXL® 2.0 standard.

Despite a lackluster launch, CASGEVY has significant potential in international markets, bolstering CRISPR's long-term value. Upcoming milestones and updates on CRISPR Therapeutics is currently sitting at historical support, at a valuation that is clinical assets are expected to drive shareholder value back to previous highs. We are bullish on CRISPR, rating it a buy with a $70 price target, as the stock currently sits at a strong support level of $40.